Navigation Links
NxStage Medical Founder and CEO Jeffrey Burbank Honored With Mass High Tech All-Star Award

LAWRENCE, Mass., Sept. 1, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Chief Executive Officer, Jeffrey H. Burbank, is among the recipients of Mass High Tech, The Voice of New England Innovation, 2011 All-Stars Awards. The All-Stars Awards recognize 15 driven and influential leaders of New England's innovation economy.


The 2011 Mass High Tech All-Stars honorees represent a broad range of technology and service sectors, including robotics, software, economic development, ecommerce, entrepreneurship, medical devices and cleantech. They were selected from more than 100 nominees recommended by the technology community.

"These All-Stars have a proven record in leading not only their own companies but in helping their industry thrive," said Mass High Tech publisher Douglas Banks. "By combining this year's awards program with the BBJ's Rising Stars in Business, we are offering our All-Stars another opportunity for mentorship while giving the younger generation access to innovative role models."

From its inception, Jeffrey Burbank has led NxStage in pioneering home hemodialysis by providing life-changing therapy to dialysis patients. Under his leadership, NxStage succeeded in developing and commercializing the NxStage® System One™, the only truly portable home hemodialysis machine cleared by the Food and Drug Administration (FDA). The System One enables a more frequent therapy schedule, which clinical data shows is associated with positive outcomes relative to conventional in-center dialysis including improved survival, improved blood pressure management and other significant clinical and lifestyle benefits.

"I am honored to be recognized among this impressive list of New England innovators," said Burbank. "With over 5,000 patients and compelling clinical data in support of the improved clinical, quality of life and survival outcomes possible with more frequent hemodialysis using the System One, NxStage has accomplished much. As the leader in home hemodialysis, we look forward to the opportunities for growth and innovation ahead."

The Innovation All-Stars and Rising Stars will be profiled in a special report on, and will be recognized at an evening awards celebration and networking reception on Wednesday, Nov. 16 at the House of Blues in Boston. For more information about the event and to register, visit

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy.  When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand.  Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements including market acceptance and demand for NxStage's System One, growth in home hemodialysis, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including Quarterly Report on Form 10Q for the quarter ended June 30, 2011

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Media Contacts:
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.

Douglas Banks
617 316 3272

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Report Third Quarter 2009 Financial Results
4. NxStage(R) Reports Significant Interim FREEDOM Study Results
5. NxStage(R) and Nordic Medcom Sign Distribution Agreement for the System One(TM)
6. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
7. Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM)
8. NxStage(R) Secures $15 Million Revolving Line of Credit
9. NxStage to Report Third Quarter Fiscal 2010 Financial Results
10. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
11. NxStage Announces Fourth Quarter 2010 Investor Conference Schedule
Post Your Comments:
(Date:12/1/2015)... 1, 2015   MabVax Therapeutics Holdings, Inc . ... it has filed an Investigational New Drug Application (IND) ... the Company,s lead fully human antibody product HuMab 5B1 ... plans to initiate the Phase I clinical trial early ... --> The planned Phase I trial will evaluate ...
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, Inc ... cycle solutions, today announced the company will showcase ... ChargeLink ® solution at the American ... Clinical Meeting . The new features are focused ... of monitoring and managing enterprise-wide pharmacy charges to ...
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Medical Alert Systems/Personal Emergency Response ... by Geography - Global Forecas" report to ... announced the addition of the "Medical Alert ... by End-User and by Geography - Global Forecas" ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... The Multiple System Atrophy Coalition has announced the launch of ... (MSA) research, timed today to coincide with Giving Tuesday 2015, a global day of ... to work and be productive, to do simple daily activities like walking to the ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, ... expansion of the company’s growing product line of food safety and seafood fraud ... Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):